Crucible Therapeutics
Specializing in developing new therapies for ALS (Lou Gehrig's disease), the most common genetic form of MND, and frontotemporal dementia (FTD).
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | £2.3m | Grant | |
| Total Funding | 000k | ||
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads